Alan H. Wells,Cecelia C. Yates-Binder,Joel S. Schuman
申请号:
US14240132
公开号:
US20140178451A1
申请日:
2012.08.23
申请国别(地区):
US
年份:
2014
代理人:
摘要:
The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of CXCR3. In some embodiments, the activator of CXCR3 is IP-10 or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal α-helix of IP-10. In other embodiments, the activator of CXCR3 is PF4 or a fragment or variant thereof.